An analysis of the baseline characteristics and outcomes, by responders and nonresponders, from the phase 3 study of (E7080) Lenvatinib in differentiated cancer of the thyroid (SELECT)

被引：0
|
作者：
Reuter, Christoph [1 ]
Yu, Xiaomin [1 ]
Baig, Mahadi [1 ]
Young, Louise [2 ]
Dutcus, Corina [1 ]
机构：
[1] Eisai Inc, Woodcliff Lake, NJ USA
[2] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
来源：
CLINICAL ENDOCRINOLOGY | 2018年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
185
引用
收藏
页码：45 / 46
页数：2
相关论文
共 39 条
  • [21] Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine- refractory differentiated thyroid cancer
    Tahara, Makoto
    Brose, Marcia S.
    Wirth, Lori J.
    Suzuki, Takuya
    Miyagishi, Hideaki
    Fujino, Katsuki
    Dutcus, Corina E.
    Gianoukakis, Andrew
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 61 - 68
  • [22] OUTCOMES BY SITE OF METASTASIS FOR PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER TREATED WITH LENVATINIB VERSUS PLACEBO: RESULTS FROM A PHASE 3, RANDOMIZED TRIAL
    Young, Louise
    Habra, Mouhammed
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 134 - 134
  • [23] Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
    Robinson, Bruce
    Schlumberger, Martin
    Wirth, Lori J.
    Dutcus, Corina E.
    Song, James
    Taylor, Matthew H.
    Kim, Sung-Bae
    Krzyzanowska, Monika K.
    Capdevila, Jaume
    Sherman, Steven I.
    Tahara, Makoto
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (11): : 4103 - 4109
  • [24] Impact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
    Tahara, M.
    Kiyota, N.
    Hoff, A. O.
    Badiu, C.
    Owonikoko, T. K.
    Dutcus, C. E.
    Suzuki, T.
    Ren, M.
    Misir, S.
    Wirth, L. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 756 - 756
  • [25] OUTCOMES WITH ODEVIXIBAT TREATMENT IN PATIENTS WITH ALAGILLE SYNDROME: ANALYSIS OF PRURITUS RESPONDERS FROM THE PHASE 3 ASSERT STUDY
    Ovchinsky, Nadia
    Aumar, Madeleine
    Baker, Alastair J.
    Baumann, Ulrich
    Bufler, Philip
    Cananzi, Mara
    Czubkowski, Piotr
    Durmaz, Ozlem
    Fischer, Ryan T.
    Indolfi, Giuseppe
    Karnsakul, Wikrom
    Lacaille, Florence
    Lee, Way Seah
    Maggiore, Giuseppe
    Rosenthal, Philip
    Ruiz, Mathias
    Sokal, Etienne
    Sturm, Ekkehard
    Van Der Woerd, Wendy
    Verkade, Henkjan J.
    Wehrman, Andrew
    Clemson, Christine
    Yu, Qifeng
    Ni, Quanhong
    Ruvido, Jessica
    Manganaro, Susan
    Mattsson, Jan P.
    HEPATOLOGY, 2023, 78 : S2106 - S2107
  • [26] Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
    Taylor, Matthew H.
    Leboulleux, Sophie
    Panaseykin, Yury
    Konda, Bhavana
    de la Fouchardiere, Christelle
    Hughes, Brett G. M.
    Gianoukakis, Andrew G.
    Park, Young Joo
    Romanov, Ilia
    Krzyzanowska, Monika K.
    Garbinsky, Diana
    Sherif, Bintu
    Pan, Jie Janice
    Binder, Terri A.
    Sauter, Nicholas
    Xie, Ran
    Brose, Marcia S.
    CANCER MEDICINE, 2023, 12 (04): : 4332 - 4342
  • [27] Hereditary transthyretin amyloidosis is associated with significant disease burden: analysis of the baseline characteristics of patients from the phase 3 study NEURO-TTR
    Damy, T.
    Maurer, M. S.
    Heitner, S. B.
    Drachman, B. M.
    Whela, C. J.
    Judge, D. P.
    Guthrie, S.
    Tai, L. J.
    Hughes, S.
    Monia, B. P.
    Ackermann, E.
    Benson, M. D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 101 - 101
  • [28] Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN)
    Taylor, M. H.
    Leboulleux, S.
    Panaseykin, Y.
    Konda, B.
    de la Fouchardiere, C.
    Hughes, B. G. M.
    Gianoukakis, A. G.
    Park, Y. J.
    Romanov, I.
    Krzyzanowska, M. K.
    Garbinsky, D.
    Sherif, B.
    Pan, J. J.
    Binder, T. A.
    Sauter, N.
    Xie, R.
    Brose, M. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1205 - S1205
  • [29] Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer
    Perol, Maurice
    Winfree, Katherine B.
    Carter, Gebra Cuyun
    Cui, Zhanglin Lin
    Bowman, Lee
    Garon, Edward B.
    LUNG CANCER, 2019, 131 : 6 - 13
  • [30] Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): A European subgroup analysis
    Smit, J. W. A.
    Brose, M. S.
    Pitoia, F.
    Lin, C-C.
    Sugitani, I.
    Alevizaki, M.
    Godbert, Y.
    Aller, J.
    Peeters, R. P.
    Pazaitou-Panayiotou, K.
    Leenhardt, L.
    Fellous, M. M.
    De Sanctis, Y.
    Schlumberger, M.
    ANNALS OF ONCOLOGY, 2017, 28
1234